O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Director Clinical Management Early Phase - Rare/specialty disease

Full-Time
$186.5k - $278.9k/yr+ Incentive opportunity
Expert
Bachelor's
Remote in USA
RemoteTravel up to 25% required.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • Comprehensive knowledge of clinical operations, the drug development process, standard operating procedures, and Good Clinical Practice and International Council for Harmonisation regulations.
  • Thorough knowledge of contract research organizations, outsourcing, and evaluation of vendor work against Statements of Work.
  • Advanced understanding of drug development principles and clinical trial implementation and management.
  • Strong knowledge of global regulatory requirements and compliance, biostatistics, data management, and medical writing.
  • Strong communication, organization, planning, analytical, problem-solving, and people-management skills.
  • Strong computer skills with demonstrated experience using Microsoft Word, Excel, PowerPoint, and Outlook.
  • Good understanding of clinical-trial software such as electronic case report forms, interactive response technology, and clinical trial management systems.
  • Ability to travel up to 25%.
  • Bachelor's degree with a minimum of 14 years of applicable pharmaceutical industry experience, including 10 years of clinical trial management experience.
  • Previous supervisory experience.
Responsibilities
  • Provide scientific clinical research and operational expertise in developing the strategy and objectives of the Global Clinical Development Plan, including performing or overseeing background research.
  • Represent Clinical Management in developing Clinical Development Plans, timelines, and budgets for Business Development opportunities.
  • Ensure program-specific standards, including case report forms, outsourcing specifications, slides, training, and templates, are developed and applied across studies.
  • Contribute to final analysis and interpretation, including clinical trial reports, publications, and internal and external presentations.
  • Develop program-level financial estimates and contribute to the multi-year long-term plan.
  • Lead program-level teams as co-chair and serve as the lead clinical management representative for designated meetings.
  • Contribute to preparing and defending clinical program documents, including investigator brochures, Investigational Medicinal Product Dossiers, annual reports, Health Authority briefing books and submissions, ongoing filing maintenance, and labeling-team support.
  • Lead development of clinical sections of regulatory documents and inspection-readiness programs where appropriate.
  • Develop scientific partnerships with key advisors in the assigned therapy area to optimize the scientific quality and innovation of clinical study design, execution, reporting, and publication.
  • Lead program-related advisory boards, committees, and meetings.
  • Support the design and implementation of a program-level health economics and outcomes research strategy, including endpoint development where necessary.
  • Serve as the contact for Medical Affairs and PBS regarding medical-information requests, public disclosure of information, and publication strategies.
  • Represent assigned programs to senior management and OPCJ, and disseminate information and tasks to team members.
  • Participate in External Service Provider partnership governance and alliance-management activities.
  • Assist the Senior Director with portfolio-level resource planning.
  • Give direction, training, and support to Clinical Management personnel within the program or compound team.
  • Participate in ongoing review of clinical-trial data, focusing on data integrity, trending, and consistency.
  • Ensure inspection-readiness activities are appropriately planned and conducted across the program.
  • Participate in program-level risk-mitigation activities.
  • Represent Clinical Management in departmental and cross-functional initiatives.
  • Lead or contribute to departmental, External Service Provider, and corporate standardization and continuous-improvement efforts.
  • Coordinate training and onboarding of new employees on corporate culture, goals, vision, and departmental policies and processes.
  • Assure compliance with departmental, standard operating procedure, compliance, and corporate training.
  • Ensure assigned staff have access to required materials, systems, and training to complete their responsibilities.
  • Set clear performance expectations and individual development plans, and provide specific and frequent performance feedback.
  • Perform other assigned duties.
Desired Qualifications
  • Advanced degree.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.